MwanzoCTSO • NASDAQ
add
Cytosorbents Corp
$ 0.84
Baada ya Saa za Kazi:(1.00%)+0.0084
$ 0.85
Imefungwa: 23 Des, 16:28:15 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 0.92
Bei za siku
$ 0.81 - $ 0.92
Bei za mwaka
$ 0.70 - $ 1.82
Thamani ya kampuni katika soko
45.72M USD
Wastani wa hisa zilizouzwa
elfu 160.02
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato | 9.39M | 6.58% |
Matumizi ya uendeshaji wa biashara | 9.61M | -24.74% |
Mapato halisi | -2.33M | 74.61% |
Kiwango cha faida halisi | -24.86 | 76.17% |
Mapato kwa kila hisa | -0.08 | 61.90% |
EBITDA | -3.95M | 41.58% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 5.69M | -31.99% |
Jumla ya mali | 47.80M | 0.48% |
Jumla ya dhima | 34.80M | 19.76% |
Jumla ya hisa | 13.00M | — |
hisa zilizosalia | 54.68M | — |
Uwiano wa bei na thamani | 3.81 | — |
Faida inayotokana na mali | -21.40% | — |
Faida inayotokana mtaji | -26.00% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
(USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
---|---|---|
Mapato halisi | -2.33M | 74.61% |
Pesa kutokana na shughuli | -2.46M | 52.73% |
Pesa kutokana na uwekezaji | elfu -298.35 | -15.77% |
Pesa kutokana na ufadhili | elfu -99.03 | -115.27% |
Mabadiliko halisi ya pesa taslimu | -2.77M | 42.13% |
Mtiririko huru wa pesa | -1.31M | 53.63% |
Kuhusu
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood.
The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects.
CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. Wikipedia
Ilianzishwa
1997
Tovuti
Wafanyakazi
186